Guardant Health Inc (GH) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Guardant Health Inc stock $112, price $152, that is 26.1% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range $16.07 – $187.22 · fair‑value band $84.07 – $140.12 · the $151.70 price screens above the $112.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.
Follow Guardant Health in your weekly email
Every Wednesday you see whether Guardant Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Show moreShow less
The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.
It also provides Shield blood test for colorectal cancer screening in adults.
In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies.
Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic.
Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests.
It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Stock analysis
Guardant Health Inc (GH) currently trades at $151.70, while our estimate is $112.10, 26% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $84.07 (bear) to $140.12 (bull), the price of $151.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Guardant Health Inc reported revenue of $982M in FY2025 versus $374M in FY2021, a compound +27.3%/yr. Reported net income was −$416M in FY2025.
Key figures
Market cap $20.0B Large · P/S ratio 16.0 · EPS (TTM) $−3.68 · Net margin −37.9% · Return on equity −4,584% · Return on assets (EBIT) −27.1% (5-year average) · Operating margin −37.1% · Revenue (TTM) $1.3B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 93% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at −26%, GH screens richer than that median.
Fair Value
Bear$84.07Fair Value $112.10Bull$140.12
Price $151.70 · Downside -26.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Quality Score breakdown
Overall quality40/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability22
How much profit the company makes from its sales and capital
Quality Growth86
Are margins and returns getting better?
Cashflow0
Do the profits arrive as real cash?
Financial strength54
Debt, balance sheet and risk of trouble
Investment82
Does it invest with discipline instead of growing at any price?
Low Volatility14
How calm the share price moves, does not count
Price momentum81
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, one officer or director bought shares worth $78,456, on Jun 15, 2026. Over the same period, 15 people sold shares worth $117.5M.
SaleMusa TariqDirector11× since Nov 19, 2025: 3,343 shares, avg. $126.29$422,188Oct 16, 202610b5-1 plan
SaleAlex M Azar IIDirector2× since Sep 16, 2026: 895 shares, avg. $173.84$155,582Oct 14, 202610b5-1 plan
SaleSteve E. KrognesDirector2× since Jun 4, 2026: 15,968 shares, avg. $150.58$2.4MSep 16, 2026
SaleDarya ChudovaChief Technology Officer3× since Dec 8, 2025: 36,124 shares, avg. $120.76$4.4MSep 15, 2026
SaleKumud KaliaChief Information Officer6× since Dec 8, 2025: 55,618 shares, avg. $106.23$5.9MSep 11, 2026
SaleAmirAli TalasazCo-Chief Executive Officer, Director5× since Dec 8, 2025: 657,500 shares, avg. $128.14$84.3MAug 21, 2026
SaleTerilyn J. MonroeChief People Officer5× since Dec 1, 2025: 123,901 shares, avg. $128.72$15.9MAug 12, 2026
SaleChris FreemanChief Commercial Officer3× since Dec 5, 2025: 119,463 shares, avg. $141.67$16.9MAug 10, 2026
SaleMedina Manuel HidalgoDirector5× since Dec 8, 2025: 6,500 shares, avg. $122.06$793,388Aug 5, 2026
SaleIan T ClarkDirector3× since Dec 5, 2025: 49,667 shares, avg. $121.92$6.1MAug 4, 2026
Plus 6 more entries from the last 12 months.
Plus 62 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.9%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+50.2%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−88.9% (2020) → −44.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
AI conclusion: Guardant Health displays a narrow moat in oncology diagnostics supported by recent FDA approval and revenue growth, yet persistent net losses, negative equity and ongoing cash burn remain its central weakness.
Main risk: A court-ordered ongoing royalty through 2033 on Guardant360, Shield and related products plus prior damages could raise costs and squeeze margins on the company's main liquid biopsy offerings.
Bull case: Guardant could leverage its Infinity AI platform and new FDA approvals to differentiate its tests, expand into longitudinal monitoring and secure broader reimbursement that offsets any royalty or competitive pressures.
Bear case: Ongoing patent royalties combined with rival tests gaining traction could raise costs, limit pricing power and slow adoption of Guardant's core products, prolonging cash burn and delaying any path to sustained profitability.
Guardant Health's recent FDA approval of Guardant360 CDx enables longitudinal testing as a companion diagnostic for breast cancer therapies. Third-quarter revenue rose 36 percent with higher full-year guidance, supported by oncology and screening growth, yet cash burn persists amid expansion. Will the new approvals drive faster profitability gains or keep margins under pressure longer?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 150 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside−26.1% · Below median
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−20.7% · Bottom 25%
Net margin (12 months)−37.9% · Bottom 25%
Operating margin (12 months)−37.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)36.1% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months)15.67× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 12
FUTURE (revenue growth)100· sector 35
PAST (return on equity)0· sector 8
HEALTH (low debt)0· sector 95
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Guardant Health Inc Fair Value". https://www.fairvalue-calculator.com/stock/GH
Frequently asked questions
Is Guardant Health Inc (GH) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $112.10 versus a price of $151.70, about 26% lower (overvalued).
What is the fair value of GH?
Our estimate for Guardant Health Inc is $112.10 (as of Nov 10, 2026), built from audited fundamentals. The current price: $151.70.
What is the quality score of GH?
Guardant Health Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Guardant Health Inc (GH)?
Our calculated price target is the estimate of $112.10 (as of Nov 10, 2026). Cautious scenario $84.07, optimistic scenario $140.12. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Guardant Health Inc stock forecast for 2026?
Our estimate puts fair value at $112.10, about 26% lower versus a price of $151.70 (overvalued). Cautious scenario $84.07, optimistic scenario $140.12. The calculation is refreshed regularly with new filings.
What is the revenue of Guardant Health Inc (GH)?
Guardant Health Inc reported trailing-twelve-month revenue of about $1.3B (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Guardant Health Inc (GH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Guardant Health Inc it is $112.10 per share (as of Nov 10, 2026), against a price of $151.70.
Is Guardant Health Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, GH trades above its calculated fair value: price $151.70, fair value $112.10, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GH?
No. The price is what the market pays today ($151.70); the fair value is what the company's own numbers justify ($112.10). For Guardant Health Inc the two are $39.60 per share apart. That gap is exactly why we show both numbers side by side.
How much is Guardant Health Inc worth?
The market values Guardant Health Inc at about $20.0B (market capitalisation, as of Nov 10, 2026). Per share that is $151.70; our models calculate a fair value of $112.10 per share.
What do the bullish and bearish scenarios say about GH?
Our models span a range for Guardant Health Inc: cautious scenario $84.07, base $112.10, optimistic $140.12 per share (as of Nov 10, 2026, price $151.70). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Guardant Health Inc (GH)?
Balance-sheet figures for Guardant Health Inc (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is GH from its 52-week high?
Guardant Health Inc trades at $151.70, about 19% below its 52-week high of $187.22 and 93% above the low of $78.60 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $112.10 is for.
Which stocks are comparable to Guardant Health Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Guardant Health Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $151.70, calculated fair value $112.10 (−26%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. Guardant Health Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Guardant Health Inc (GH)?
The closing price on Nov 13, 2026 was $151.70. Our estimate is $112.10, about 26% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Guardant Health Inc right now?
The price sits above even our optimistic bull case ($140.12). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Guardant Health Inc
How large is the market capitalisation of Guardant Health Inc (GH)?
The market capitalisation of Guardant Health Inc is $20.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Guardant Health Inc (GH)?
The price-to-sales ratio of Guardant Health Inc is 16.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Guardant Health Inc (GH)?
Earnings per share at Guardant Health Inc are $−3.68. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Guardant Health Inc (GH)?
The net margin of Guardant Health Inc is −37.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Guardant Health Inc (GH)?
The return on equity (ROE) of Guardant Health Inc is −4,584% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Guardant Health Inc (GH)?
On an EBIT basis the return on assets of Guardant Health Inc is −27.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Guardant Health Inc (GH)?
The operating margin of Guardant Health Inc is −37.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Guardant Health Inc (GH)?
Revenue at Guardant Health Inc is growing +36.1% versus a year earlier (3y avg +29.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Guardant Health Inc (GH) generate?
The free cash flow of Guardant Health Inc is −$233M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Guardant Health Inc (GH) carry?
The net debt of Guardant Health Inc is $1.3B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Guardant Health Inc in the live analysis
One click puts Guardant Health Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 10, 2026
